LY2090314

Catalog No. A12741

LY2090314是糖原合酶激酶3(GSK-3)的有效抑制剂,在许多途径中起重要作用,包括蛋白质合成的起始,细胞增殖,细胞分化和凋亡。
  • Yuki Shimizu, .et al. GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer, NPJ Precis Oncol, 2022, Mar 17;6(1):16 PMID: 35301419
Catalog Num A12741
M. Wt 512.53
Formula C28H25FN6O3
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 603288-22-8
Synonyms LY 2090314, LY-2090314
SMILES C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7
LY2090314是糖原合酶激酶3(GSK-3)的有效抑制剂,在许多途径中起重要作用,包括蛋白质合成的起始,细胞增殖,细胞分化和凋亡。
Targets
GSK-3β GSK-3α
0.9 nM1.5 nM
In vitro (25°C) DMSO 93 mg/mL (181.45 mM)
Water Insoluble
Ethanol Warmed: 2 mg/mL (3.9 mM)
In vivo 5% DMSO+45% PEG 300+ddH2O 16 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 19.51 mL 97.56 mL 195.11 mL
0.5 mM 3.9 mL 19.51 mL 39.02 mL
1 mM 1.95 mL 9.76 mL 19.51 mL
5 mM 0.39 mL 1.95 mL 3.9 mL

*The above data is based on the productmolecular weight 512.53. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.